Millendo Therapeutics, Inc. announced that on December 16, 2019, Randall Whitcomb, M.D., a member of the board of directors of the company and a member of the Compensation Committee and the Audit Committee of the Board, notified the company that he will retire from his positions on the Board and on the committees effective as of December 17, 2019. Dr. Whitcomb retired for personal reasons and not as a result of any disagreement with the company on any matter relating to the company’s operations, policies or practices. On December 17, 2019, the board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board appointed Dr. Geoff Nichol to serve on the Board as a Class II director, filling the vacancy following the retirement of Dr. Whitcomb, and as a member of the Nominating Committee, each effective as of December 17, 2019. As a Class II director, Dr. Nichol’s term expires at the annual meeting of the stockholders to be held in 2020. Dr. Nichol is currently the Chief Medical Officer of BioMarin Pharmaceutical Inc. Prior to joining BioMarin in 2016 and since 2011, Dr. Nichol served as the Executive Vice President, Research and Development of Sangamo Therapeutics, Inc.